Preview

Научно-практическая ревматология

Расширенный поиск

Проатерогенные нарушения обмена липидов и липопротеидов крови у больных ревматоидным артритом

https://doi.org/10.14412/1995-4484-2017-311-320

Полный текст:

Аннотация

Ведущее значение в развитии атеросклеротического поражения сосудов при ревматоидном артрите (РА) отводят нарушениям в системе транспорта холестерина крови. В статье проанализирован липидный профиль крови у больных с нелеченым РА. Представлены данные о влиянии воспаления на проатерогенные нарушения обмена липидов и липопротеидов, обозначена необходимость изучения подфракций липопротеидов высокой плотности и их функции – обратного транспорта холестерина у больных РА – как более перспективного метода оценки сердечно-сосудистого риска. 

Об авторах

Е. В. Герасимова
ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия

115522 Москва, Каширское шоссе, 34А



Т. В. Попкова
ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия

115522 Москва, Каширское шоссе, 34А



Д. С. Новикова
ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой», Москва
Россия

115522 Москва, Каширское шоссе, 34А


Конфликт интересов:

34A, Kashirskoe Shosse, Moscow 115522 



Список литературы

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685-95. doi: 10.1056/NEJMra043430

2. Read TE, Grunfeld C, Kumwenda ZL, et al. Triglyceride-rich lipoproteins prevent septic death in rats. J Exp Med. 1995 Jul 1;182(1):267-72. doi: 10.1084/jem.182.1.267

3. Hardardottir I, Kunitake ST, Moser AH, et al. Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Invest. 1994 Sep;94(3):1304-9. doi: 10.1172/JCI117449

4. Memon RA, Staprans I, Noor M, et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1536-42. doi: 10.1161/01.ATV.20.6.1536

5. Haas MJ, Mooradian AD. Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease. Diabetes Metab Res Rev. 2010 Feb;26(2):90-9. doi: 10.1002/dmrr.1057

6. Straub RH, Cutolo M, Buttgereit F, Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med. 2010 Jun;267(6):543-60. doi: 10.1111/j.1365-2796.2010.02218.x. Epub 2010 Jan 28.

7. McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009 Mar 3;119(8):1135-45. doi: 10.1161/CIRCULATIONAHA.108.810721. Epub 2009 Feb 16.

8. Wu Y, Cui J, Bao X, et al. Triptolide attenuates oxidative stress, NF-kappaB activation and multiple cytokine gene expression in murine peritoneal macrophage. Int J Mol Med. 2006 Jan;17(1):141-50.

9. Kralova A, Kralova Lesna I, Poledne R. Immunological aspects of atherosclerosis. Physiol Res. 2014;63 Suppl 3:S335-42.

10. Lahoute C, Herbin O, Mallat Z, Tedgui A. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol. 2011 Jun;8(6):348-58. doi: 10.1038/nrcardio.2011.62. Epub 2011 Apr 19.

11. Adibhatla RM, Dempsy R, Hatcher JF. Integration of cytokine biology and lipid metabolism in stroke. Front Biosci. 2008 Jan 1;13:1250-70. doi: 10.2741/2759

12. Akita K, Isoda K, Shimada K, Daida H. Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice. J Am Heart Assoc. 2015 Mar 13;4(3):e001469. doi: 10.1161/JAHA.114.001469

13. Jovinge S, Ares MP, Kallin B, Nilsson J. Human monocytes/macrophages release TNF-alpha in response to OxLDL. Arterioscler Thromb Vasc Biol. 1996 Dec;16(12):1573-9. doi: 10.1161/01.ATV.16.12.1573

14. Niemann-Jönsson A, Dimayuga P, Jovinge S, et al. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-alpha expression. Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2205-11. doi: 10.1161/01.ATV.20.10.2205

15. Zhou Z, Connell MC, MacEwan DJ. TNFR1-induced NFkappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. Cell Signal. 2007 Jun;19(6):1238-48. doi: 10.1016/j.cellsig.2006.12.013. Epub 2007 Jan 18.

16. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87-91. doi: 10.1126/science.7678183

17. Kaplon-Cieslicka A, Postula M, Rosiak M, et al. Association of adipokines and inflammatory markers with lipid control in type 2 diabetes. Pol Arch Med Wewn. 2015;125(6):414-23. doi: 10.20452/pamw.2880. Epub 2015 May 15.

18. Jovinge S, Hamsten A, Tornvall P, et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism. 1998 Jan;47(1):113-8. doi: 10.1016/S0026- 0495(98)90203-7

19. Ahmed W, Orasanu G, Nehra V, et al. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res. 2006 Mar 3;98(4):490-8. doi: 10.1161/01.RES.0000205846.46812.be. Epub 2006 Jan 26.

20. Ettinger WH Jr, Sun WH, Binkley N, et al. Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus monkeys. J Gerontol A Biol Sci Med Sci. 1995 May;50(3):M137-40. doi: 10.1093/gerona/50A.3.M137

21. Lazzerini PE, Lorenzini S, Selvi E, et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1β-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheum. 2007;25:696-700.

22. Yokota K, Mioyoshi F, Myazaki K, et al. High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol. 2008;35:193-200.

23. Gotsman I, Stabholz A, Planer D, et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J. 2008 Jul;10(7):494-8.

24. Ridker PM. Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur Heart J. 2014 Mar;35(9):540-3. doi: 10.1093/eurheartj/eht398. Epub 2013 Nov 7.

25. Cheng HF, Feng Y, Jiang DM, et al. Protective function of tocilizumab in human cardiac myocytes ischemia reperfusion injury. Asian Pac J Trop Med. 2015 Jan;8(1):48-52. doi: 10.1016/S1995-7645(14)60186-3

26. Zimmermann O, Li K, Zaczkiewicz M, et al. C-reactive protein in human atherogenesis: facts and fiction. Mediators Inflamm. 2014;2014:561428. doi: 10.1155/2014/561428. Epub 2014 Apr 1.

27. Agrawal A, Gang TB, Rusinol AE. Recognition functions of pentameric C-reactive protein in cardiovascular disease. Mediators Inflamm. 2014;2014:319215. doi: 10.1155/2014/319215. Epub 2014 May 19.

28. Strang F, Schunkert H. C-reactive protein and coronary heart disease: all said – is not it? Mediators Inflamm. 2014;2014:757123. doi: 10.1155/2014/757123. Epub 2014 Apr 7.

29. Fu T, Borensztajn J. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J. 2002 Aug 15;366(Pt 1):195-201. doi: 10.1042/bj20020045

30. Wang MS, Black JC, Knowles MK, Reed SM. C-reactive protein (CRP) aptamer binds to monomeric but not pentameric form of CRP. Anal Bioanal Chem. 2011 Sep;401(4):1309-18. doi: 10.1007/s00216-011-5174-1. Epub 2011 Jul 2.

31. Singh SK, Suresh MV, Hammond DJ Jr, et al. Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. Clin Chim Acta. 2009 Aug;406(1-2):151-5. doi: 10.1016/j.cca.2009.06.018. Epub 2009 Jun 21.

32. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001 Mar 6;103(9):1194-7. doi: 10.1161/01.CIR.103.9.1194

33. Manolov DE, Rö cker C, Hombach V, et al. Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with FcgammaRIIa. Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2372-7. doi: 10.1161/01.ATV.0000147407.17137.02. Epub 2004 Oct 14.

34. Li SF, Hu YW, Zhao JY, et al. Ox-LDL upregulates CRP expression through the IGF2 pathway in THP-1 macrophages. Inflammation. 2015 Apr;38(2):576-83. doi: 10.1007/s10753-014- 9964-4

35. Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of atherosclerosis. Atherosclerosis. 1999 Aug;145(2):375-9. doi: 10.1016/S0021- 9150(99)00105-7

36. Pegues MA, McCrory MA, Zarjou A, Szalai AJ. C-reactive protein exacerbates renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2013 Jun 1;304(11):F1358-65. doi: 10.1152/ajprenal.00476.2012. Epub 2013 Mar 27.

37. Anatoliotakis N, Deftereos S, Bouras G, et al. Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease. Curr Top Med Chem. 2013;13(2):115-38. doi: 10.2174/1568026611313020004

38. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med. 2000 Jun 15;28(12):1717-25. doi: 10.1016/S0891-5849(00)00229-X

39. Brennan ML, Penn MS, van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003 Oct 23;349(17):1595-604. doi: 10.1056/NEJMoa035003

40. Salonen I, Huttunen K, Hirvonen MR, et al. Serum myeloperoxidase is independent of the risk factors of atherosclerosis. Coron Artery Dis. 2012 Jun;23(4):251-8. doi: 10.1097/MCA.0b013e328353a676

41. O'Flynn J, Dixon KO, Faber Krol MC, et al. Myeloperoxidase directs properdin-mediated complement activation. J Innate Immun. 2014;6(4):417-25. doi: 10.1159/000356980. Epub 2013 Dec 20.

42. Delporte C, van Antwerpen P, Vanhamme L, et al. Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. Mediators Inflamm. 2013;2013:971579. doi: 10.1155/2013/971579. Epub 2013 Jul 24.

43. Getz GS, Reardon CA. Myeloperoxidase-mediated dysfunctional high-density lipoprotein. Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):695-6. doi: 10.1161/ATVBAHA.114.303282

44. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995 Dec;96(6):2758- 67. doi: 10.1172/JCI118345

45. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001 May 8;103(18):2283-8. doi: 10.1161/01.CIR.103.18.2283

46. Watanabe J, Charles-Schoeman C, Miao Y, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1828-37. doi: 10.1002/art.34363. Epub 2012 Jan 9.

47. Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007 Aug;18(4):427-34. doi: 10.1097/MOL.0b013e3282364a17

48. Besler C, Heinrich K, Riwanto M, et al. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr Pharm Des. 2010 May;16(13):1480-93. doi: 10.2174/138161210791051013

49. Glomset JA. The plasma lecithin: cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-67.

50. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973 Jun 29; 180(4093):1332-9. doi: 10.1126/science.180.4093.1332

51. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-9. doi: 10.1016/S0140-6736(75)92376-4

52. Yamashita S, Sakai N, Hirano K, et al. Roles of plasma lipid transfer proteins in reverse cholesterol transport. Review. Front Biosci. 2001 Mar 1;6:D366-87. doi: 10.2741/A616

53. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol. 2010 Jun;21(3):229-38. doi: 10.1097/MOL.0b013e328338472d

54. Ji Y, Jian B, Wang N, et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem. 1997 Aug 22;272(34):20982-5. doi: 10.1074/jbc.272.34.20982

55. Климов АН, Никульчева НГ. Обмен липидов и липопротеидов и его нарушения. Cанкт-Петербург: Питер; 1999 [Klimov AN, Nikul'cheva NG. Obmen lipidov i lipoproteidov i ego narusheniya [Exchange of lipids and lipoproteins and its violation]. Sankt-Peterburg: Piter; 1999].

56. Attie AD, Kastelein JP, Hayden MR. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res. 2001 Nov;42(11):1717-26.

57. Brunham LR, Kruit JK, Iqbal J, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116:1052-62. doi: 10.1172/JCI27352

58. Von Eckardstein A, Chirazi A, Schuler-Lü ttmann S, et al. Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I. J Lipid Res. 1998 May;39(5):987-98.

59. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001 Jul;42(7):1007-17. doi: 10.1101/gr.gr-1649r

60. Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001 Jun 29;276(26):23742-7. doi: 10.1074/jbc.M102348200

61. Ragozin S, Niemeier A, Laatsch A, et al. Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arterioscler Thromb Vasc Biol. 2005;25:1433-8. doi: 10.1161/01.ATV.0000166616.86723.d0

62. Yancey PG, de la Llera-Moya M, Swarnakar S, et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem. 2000 Nov 24;275(47):36596-604. doi: 10.1074/jbc.M006924200

63. Yancey PG, de la Llera-Moya M, Drazul-Schrader D, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801. doi: 10.1161/ATVBAHA.109.199158

64. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 2006;113(21):2548-55.

65. De la Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801. doi: 10.1161/ATVBAHA.109.199158. Epub 2010 Jan 14.

66. Zhou H, Tan KCB, Shiu SWM, Wong Y. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy. Diabetes Metab Res Rev. 2008;24:617-23. doi: 10.1002/dmrr.895

67. Favari E, Lee M, Calabresi L, et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type Imediated lipid efflux to high density lipoprotein. J Biol Chem. 2004;279:9930-6. doi: 10.1074/jbc.M312476200

68. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National guidelanes]. Moscow: GEOTARMedia; 2008. P. 290-331].

69. Ranganath VK, Maranian P, Elashoff DA, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford). 2013 Oct;52(10):1809-17. doi: 10.1093/rheumatology/ket224. Epub 2013 Jun 27.

70. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003 Mar 11;107(9):1303-7. doi: 10.1161/01.CIR.0000054612.26458.B2

71. Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012 Sep;71(9):1524-9. doi: 10.1136/annrheumdis-2011-200726

72. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005 Feb;52(2):402-11. doi: 10.1002/art.20853

73. Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M. Cardiovascular diseases in patients with rheumatoid arthritis. Scand J Rheumatol. 2013;42(2):131-5. doi: 10.3109/03009742.2012.723747. Epub 2012 Dec 18.

74. Holmqvist ME, Wedren S, Jacobsson LT, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med. 2010 Dec;268(6):578-85. doi: 10.1111/j.1365- 2796.2010.02260.x

75. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010 Feb;69(2):325-31. doi: 10.1136/ard.2009.113696. Epub 2009 Sep 22.

76. Dessein PH, Joffe BI. When is a patient with rheumatoid arthritis at risk for cardiovascular disease? J Rheumatol. 2006 Feb;33(2):201-3.

77. Kaplan MJ. Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. Rheum Dis Clin North Am. 2010 May;36(2):405-26. doi: 10.1016/j.rdc.2010.02.002

78. Попкова ТВ, Новикова ДС, Писарев ВВ и др. Факторы риска кардиоваскулярных заболеваний при ревматоидном артрите. Научно-практическая ревматология. 2009;47(3):4-11 [Popkova TV, Novikova DS, Pisarev VV, et al. Risk factors of cardiovascular diseases in rheumatoid arthritis. NauchnoPrakticheskaya Revmatologiya = Rheumatology Science and Practice. 2009;47(3):4-11 (In Russ.)]. doi: 10.14412/1995-4484- 2009-1306

79. Zhang J, Chen L, Delzell E, et al. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2014 Jul;73(7):1301-8. doi: 10.1136/annrheumdis-2013-204715. Epub 2014 May 5.

80. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun. 2007 MarMay;28(2-3):69-75. doi: 10.1016/j.jaut.2007.02.004. Epub 2007 Apr 16.

81. Lazarevic MB, Vitic J, Mladenovic V, et al. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum. 1992 Dec;22(3):172-8. doi: 10.1016/0049- 0172(92)90017-8

82. Dessein PH, Stanwix AE, Moomal Z. Rheumatoid arthritis and cardiovascular disease may share similar risk factors. Rheumatology (Oxford). 2001 Jun;40(6):703-4. doi: 10.1093/rheumatology/40.6.703

83. Kim SH, Lee CK, Lee EY, et al. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol Int. 2004 Jul;24(4):230-3. doi: 10.1007/s00296-003-0358-4. Epub 2003 Nov 20.

84. Myasoedova E, Crowson CS, Kremers HM, et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010 Jul;69(7):1310-4. doi: 10.1136/ard.2009.122374. Epub 2009 Oct 23.

85. Liao KP, Cai T, Gainer VS, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken). 2013 Dec;65(12):2046-50. doi: 10.1002/acr.22091

86. Choy E, Sattar N. Interpreting lipid levels in the context of highgrade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68:460-9. doi: 10.1136/ard.2008.101964

87. Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoid and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:842-5. doi: 10.1136/ard.62.9.842

88. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011 Mar;70(3):482-7. doi: 10.1136/ard.2010.135871

89. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment – a prospective, controlled study. Arthritis Res Ther. 2006;8(3):R82. doi: 10.1186/ar1952. Epub 2006 Apr 28.

90. Chavan VU, Ramavataram D, Patel PA, Rupani MP. Evaluation of serum magnesium, lipid profile and various biochemical parameters as risk factors of cardiovascular diseases in patients with rheumatoid arthritis. J Clin Diagn Res. 2015 Apr;9(4):BC01-5. doi: 10.7860/JCDR/2015/12206.5740. Epub 2015 Apr 1.

91. Van de Stadt LA, van Sijl AM, van Schaardenburg D, Nurmohamed MT. Dyslipidaemia in patients with seropositive arthralgia predicts the development of arthritis. Ann Rheum Dis. 2012;71:1915-6. doi: 10.1136/annrheumdis-2012-201709

92. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol. 1999 Aug;26(8):1701-4.

93. White D, Fayez S, Doube A. Atherogenic lipid profiles in rheumatoid arthritis. N Z Med J. 2006 Aug 18;119(1240):U2125.

94. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis – the Third National Health and Nutrition Examination Survey. J Rheumatol. 2005 Dec;32(12):2311-6.

95. Govindan KP, Basha S, Ramesh V, et al. A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects. J Pharm Bioallied Sci. 2015 Apr;7(Suppl 1):S22-5. doi: 10.4103/0975-7406.155767

96. Attar SM. Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity. Saudi Med J. 2015 Jun;36(6):685-91. doi: 10.15537/smj.2015.6.10557

97. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002;4(5):R5. doi: 10.1186/ar428

98. Hurt-Camejo E, Paredes S, Masana L, et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum. 2001 Dec;44(12):2761-7. doi: 10.1002/1529- 0131(200112)44:123.0.CO;2-5

99. Boyer JF, Gourraud PA, Cantagrel A, et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine. 2011 Mar;78(2):179-83. doi: 10.1016/j.jbspin.2010.07.016. Epub 2010 Sep 17.

100. Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of antitumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1282-91. doi: 10.1002/acr.21693

101. Gonzalez A, Maradit Kremers H, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008 Jan;67(1):64-9. doi: 10.1136/ard.2006.059980. Epub 2007 May 21.

102. Попкова ТВ, Новикова ДС, Новиков АА и др. Роль нарушений в системе транспорта холестерина крови в развитие атеросклероза при ревматоидном артрите. Научно-практическая ревматология. 2007;45(5):4-10 [Popkova TV, Novikova DS, Novikov AA, et al. Role of blood cholesterol transport system disturbances in atherosclerosis development in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2007;45(5):4-10. (In Russ.)]. doi: 10.14412/1995-4484-2007-14.

103. Pozzi FS, Maranhao RC, Guedes LK, et al. Plasma kinetics of an LDL-like non-protein nanoemulsion and transfer of lipids to high-density lipoprotein (HDL) in patients with rheumatoid arthritis. J Clin Lipidol. 2015 Jan-Feb;9(1):72-80. doi: 10.1016/j.jacl.2014.10.004. Epub 2014 Nov 4.

104. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011 Jan 13;364(2):127-35. doi: 10.1056/NEJMoa1001689

105. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014 Dec 18;371(25):2383-93. doi: 10.1056/NEJMoa1409065. Epub 2014 Nov 18.

106. Asztalos BF, Collins D, Cupples LA, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veteran's affairs HDL Intervention trial. Aterioscler Throm Vasc Biol. 2005;25:2185-91. doi: 10.1161/01.ATV.0000183727.90611.4f

107. Lamon-Fava S, Herrington DM, Reboussin DM, et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 2008;28:575-9. doi: 10.1161/ATVBAHA.107.157123

108. Watanabe H, Soderlund S, Soro-Paavonen A, et al. Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol. 2006;26:897-902. doi: 10.1161/01.ATV.0000209577.04246.c0

109. Williams PT, Feldman DE. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis. 2011 Jan;214(1):196-202. doi: 10.1016/j.atherosclerosis.2010.10.024. Epub 2010 Oct 23.

110. Superko HR, Pendyala L, Williams PT, et al. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol. 2012 Nov-Dec;6(6):496-523. doi: 10.1016/j.jacl.2012.03.001. Epub 2012 Mar 23.

111. Arts E, Fransen J, Lemmers H, et al. High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study. Arthritis Res Ther. 2012 May 14;14(3):R116. doi: 10.1186/ar3842

112. Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995 Dec;96(6):2758- 67. doi: 10.1172/JCI118345

113. McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006 Aug;54(8):2541-9. doi: 10.1002/art.21976

114. Charles-Schoeman C, Watanabe J, Lee YY, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 2009 Oct;60(10):2870-9. doi: 10.1002/art.24802

115. Watanabe J, Charles-Schoeman C, Miao Y, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1828-37. doi: 10.1002/art.34363. Epub 2012 Jan 9.

116. Feijoo M, Tunez I, Ruiz A, et al. Oxidative stress biomarkers as indicator of chronic inflammatory joint diseases stage. Reumatol Clin. 2010 Mar-Apr;6(2):91-4. doi: 10.1016/j.reuma.2008.12.016. Epub 2009 Jul 31.

117. Vivekanandan-Giri A, Slocum JL, Byun J, et al. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis. 2013 Oct;72(10):1725-31. doi: 10.1136/annrheumdis-2012-202033. Epub 2013 Jan 12.

118. Wang W, Jian Z, Guo J, Ning X. Increased levels of serum myeloperoxidase in patients with active rheumatoid arthritis. Life Sci. 2014 Nov 4;117(1):19-23. doi: 10.1016/j.lfs.2014.09.012. Epub 2014 Sep 28.

119. Nzeusseu Toukap A, Delporte C, Noyon C, et al. Myeloperoxidase and its products in synovial fluid of patients with treated or untreated rheumatoid arthritis. Free Radic Res. 2014 Apr;48(4):461-5. doi: 10.3109/10715762.2014.886327. Epub 2014 Feb 20.

120. Charles-Schoeman C, Lee YY, Grijalva V, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012 Jul;71(7):1157-62. doi: 10.1136/annrheumdis-2011-200493. Epub 2012 Jan 20.

121. Robins SJ, Lyass A, Brocia RW, et al. Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study. Atherosclerosis. 2013 May;228(1):230-6. doi: 10.1016/j.atherosclerosis.2013.01.046. Epub 2013 Feb 18.

122. Ferraz-Amaro I, Gonzalez-Gay MA, Garcia-Dopico JA, DiazGonzalez F. Cholesteryl ester transfer protein in patients with rheumatoid arthritis. J Rheumatol. 2013 Jul;40(7):1040-7. doi: 10.3899/jrheum.121507. Epub 2013 May 15.

123. Voloshyna I, Modayil S, Littlefield MJ, et al. Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages. Exp Biol Med (Maywood). 2013 Oct;238(10):1192-7. doi: 10.1177/1535370213503262. Epub 2013 Sep 2.

124. Liao KP, Playford MP, Frits M, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015 Jan 30;4(2). pii: e001588. doi: 10.1161/JAHA.114.001588

125. Navarro-Millan I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2016 Feb;75(2):341-7. doi: 10.1136/annrheumdis-2013-204987. Epub 2015 Jan 21.


Для цитирования:


Герасимова Е.В., Попкова Т.В., Новикова Д.С. Проатерогенные нарушения обмена липидов и липопротеидов крови у больных ревматоидным артритом. Научно-практическая ревматология. 2017;55(3):311-320. https://doi.org/10.14412/1995-4484-2017-311-320

For citation:


Gerasimova E.V., Popkova T.V., Novikova D.S. PROATHEROGENIC LIPID AND LIPOPROTEIN METABOLIC DISTURBANCES IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology Science and Practice. 2017;55(3):311-320. (In Russ.) https://doi.org/10.14412/1995-4484-2017-311-320

Просмотров: 609


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)